Grossman Fred 4

What Happened

• Fred Grossman, Chief Medical Officer of Coya Therapeutics (COYA), received a derivative equity award on 2026-01-22 covering 140,041 shares. The Form 4 lists a per-share amount of $0.00, indicating no cash paid at grant. This is a grant (award) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22; Form filed: 2026-01-26 (filed within the SEC’s 2-business-day window).
• Shares/units granted: 140,041 (reported as a derivative award, code A).
• Price listed on Form 4: $0.00 per share (no cash outlay recorded at grant).
• Vesting: Shares underlying the option vest in monthly installments over the next 36 months (service-based vesting).
• Change-in-control: Upon a change in control, the shares underlying the option will vest and the option become immediately exercisable (per the Issuer's 2021 Equity Incentive Plan, as amended).
• Shares owned after the transaction: not disclosed in the provided data.
• Filing timeliness: Filed Jan 26 for a Jan 22 transaction — within the required reporting window (not late).

Context

• This was an equity award (derivative grant under the company’s equity plan), not an immediate stock purchase or sale. Such grants are typically compensation/retention tools and vest over time, so they do not represent immediate insider buying or selling activity. The $0.00 listing means Grossman did not pay cash at grant; payout or dilution depends on future vesting and any exercise terms.